| Name | Trilaciclib |
| Description | Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC₅₀ values of 1 nM and 4 nM respectively. It transiently and reversibly induces G1 cell cycle arrest, mitigates chemotherapy-induced myelosuppression, and enhances antitumour immunity, making it applicable across multiple cancers. |
| In vitro | Methods: HS68 cells were treated with Trilaciclib (10-3000nM, 24 hours), fixed and stained with propidium iodide and RNAse A, then analyzed using a Cyan ADP Analyzer.
Results: After 24 hours of treatment with 300 nM trilaciclib, the proportion of HS68 cells in the G1 phase reached as high as 98%.[1] |
| In vivo | Method: FVB/N mice were orally administered Trilaciclib (50, 100, 150 mg/kg, single dose), followed by EdU injection to measure the proliferation of bone marrow Lineage-negative cells.
Results: Trilaciclib exhibited a dose-dependent effect, effectively suppressing the proliferation of bone marrow HSPCs. [1] |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (10.08 mM)
|
| Keywords | Trilaciclib | CDK6 | CDK4 |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Sodium citrate monobasic | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Dinaciclib |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
